Another Perspective on rFC
![horseshoe-crab horseshoe-crab](/images/default-source/default-album/pda-letter/new-portal/articles/september-2017/horseshoe-crab.jpg?sfvrsn=a62d8d8e_0)
I have noticed that a few articles have been published recently questioning the use of recombinant Factor C (rFC) assays to detect endotoxin contamination in parenterally administered pharmaceuticals or implanted medical devices [Editor’s Note: See list of previous rFC-related articles at end of article.]. There seems to be some confusion regarding the history of the development of the limulus amebocyte assay (LAL) assay, the development of the rFC assay and its regulatory status.